DBV Technologies (NASDAQ:DBVT) Sets New 52-Week Low - What's Next?

Key Points

• DBV Technologies fell to a new 52-week low of $8.90, last trading at $9.03 after closing at $9.55, while remaining below its 50-day and 200-day moving averages.
• Analyst sentiment is mixed but leans positive: five analysts rate the stock Buy versus one Sell, producing a “Moderate Buy” consensus and an average price target of $48.50.
• Institutional investors and hedge funds own approximately 71.74% of the company. DBV is a clinical-stage biotech developing needle-free treatments for food allergies, led by its investigational Viaskin Peanut patch.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) hit a new 52-week low on Wednesday. The company traded as low as $8.90 and last traded at $9.03, with a volume of 344,103 shares trading hands. The stock had previously closed at $9.55.

Analysts Set New Price Targets

Several research firms have recently weighed in on DBVT. Cantor Fitzgerald reissued an "overweight" rating on shares of DBV Technologies in a report on Thursday, September 10th. Wall Street Zen downgraded shares of DBV Technologies from a "hold" rating to a "sell" rating in a research report on Saturday, July 4th. Weiss Ratings cut shares of DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, July 17th. Citigroup reissued a "market outperform" rating on shares of DBV Technologies in a research report on Wednesday, September 30th. Finally, HC Wainwright restated a "buy" rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, DBV Technologies currently has an average rating of "Moderate Buy" and an average target price of $48.50.

DBV Technologies Trading Down 5.4%

The firm's fifty day moving average is $12.70 and its 200-day moving average is $16.01.

Hedge Funds Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in DBVT. Vivo Capital LLC grew its holdings in DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock worth $55,726,000 after acquiring an additional 205,943 shares during the period. ADAR1 Capital Management LLC purchased a new stake in shares of DBV Technologies during the 1st quarter worth $21,159,000. Perceptive Advisors LLC purchased a new stake in shares of DBV Technologies during the 1st quarter worth $20,146,000. Atika Capital Management LLC grew its stake in shares of DBV Technologies by 31.1% during the 1st quarter. Atika Capital Management LLC now owns 271,300 shares of the company's stock worth $5,667,000 after purchasing an additional 64,419 shares during the period. Finally, Elmind Capital LP purchased a new position in shares of DBV Technologies in the 1st quarter valued at about $5,536,000. Institutional investors and hedge funds own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's technology is designed to deliver therapeutic proteins through the skin without needles, with the goal of gradually modifying the immune system's response to specific allergens.

DBV Technologies' principal product candidate is Viaskin Peanut, an investigational epicutaneous immunotherapy designed to expose patients to small amounts of peanut protein through a wearable patch.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.